Perspective Therapeutics Inc (CATX)

$3.05 -0.04 (-1.29%)
Market Cap 352.40M
Revenue (ttm) 880,000.00
Net Income (ttm) -103.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,718.18%
Debt to Equity Ratio 0.00
Volume 2,810,100
Avg Vol 1,935,044
Day's Range N/A - N/A
Shares Out 114.05M
Stochastic %K 24%
Beta 1.74
Analysts Strong Sell
Price Target $12.79

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a b...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
Alacrity2
Alacrity2 Jul. 15 at 1:52 AM
$CATX I don’t remember seeing this… https://www.linkedin.com/posts/perspective-therapeutics_radiopharmaceuticals-oncology-precisionmedicine-ugcPost-7472649491922477057-7vpq?utm_medium=ios_app&rcm=ACoAACVaBNsBrvfIvbW16ta28vS1MkGGk6XkjWE&utm_source=social_share_video_v2&utm_campaign=share_via
0 · Reply
Raisehellpraisedale
Raisehellpraisedale Jul. 14 at 9:25 PM
$CATX hey yall I’m new here and considering a position after I do some further research. If anyone has some interesting knowledge or information about their products or their personnel I would appreciate links or summaries! So far it seems like an obvious candidate for a BO but I’m only getting started in my process
1 · Reply
noble23
noble23 Jul. 14 at 3:47 PM
$CATX markets up Catx down, Markets down Catx is up? Why? This has been going on for a long time makes no sense.
1 · Reply
Miura1957
Miura1957 Jul. 14 at 3:24 PM
$CATX afternoon rally?
1 · Reply
StockConsultant
StockConsultant Jul. 14 at 1:17 PM
$CATX Perspective Therapeutics stock watch, attempting to move higher off the 3.06 support area at https://stockconsultant.com/?CATX Long Trade Target 1: 3.6 Profit: 16.5% Stop/Trailing Stop: 2.91 Loss: 5.8% P/L ratio: 2.8 : 1 - Good Target 2: 3.83 Profit: 23.9% P/L ratio: 4.1 : 1 - Excellent Extreme rally BULLISH [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom. [Positioning] at support [Timing] Strong bullish 3 day candlestick pattern with Strong 3 day accumulation. [Timing] Strong bullish 1 day moneyflow BEARISH None
0 · Reply
JDinvestments
JDinvestments Jul. 14 at 12:27 PM
$CATX $22 incoming goodluck STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀 👋👋👋🤡🤡🤡 later bitches out !!!
0 · Reply
Newmoves
Newmoves Jul. 14 at 11:32 AM
$CATX what will be the share price when they announce the merger acquisition? $6?
1 · Reply
morty104
morty104 Jul. 14 at 10:35 AM
$CATX up 2, down 6, up 2, down 5, up 2, down 5…math ain’t mathing.
0 · Reply
morty104
morty104 Jul. 14 at 10:33 AM
$CATX YES! They never disappoint; “SEND IN THE ACQUISITION/MERGER/BUYOUT PEOPLE”. Same strategy every time.
0 · Reply
Satann
Satann Jul. 13 at 8:09 PM
$CATX last few weeks look likes share swaps. Are they readying for acquisition?
3 · Reply
Latest News on CATX
Perspective Therapeutics management to meet virtually with BTIG

2026-07-10T17:55:37.000Z - 4 days ago

Perspective Therapeutics management to meet virtually with BTIG

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Jul 8, 2026, 6:30 AM EDT - 7 days ago

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Perspective Therapeutics management to meet virtually with BTIG

2026-06-26T19:25:28.000Z - 18 days ago

Perspective Therapeutics management to meet virtually with BTIG

Perspective announces first patient dosed with (212Pb)VMT-alpha-NET

2026-06-03T11:10:47.000Z - 6 weeks ago

Perspective announces first patient dosed with (212Pb)VMT-alpha-NET

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Jun 3, 2026, 6:30 AM EDT - 6 weeks ago

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

May 21, 2026, 5:51 PM EDT - 7 weeks ago

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 2:05 PM EDT - 2 months ago

Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Perspective Therapeutics doses first patients in two Phase 1/2a studies

2026-05-18T10:35:48.000Z - 2 months ago

Perspective Therapeutics doses first patients in two Phase 1/2a studies

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

May 18, 2026, 6:30 AM EDT - 2 months ago

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 5:20 PM EDT - 2 months ago

Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Perspective Therapeutics price target lowered to $6 from $7 at BofA

2026-05-12T16:04:03.000Z - 2 months ago

Perspective Therapeutics price target lowered to $6 from $7 at BofA

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

2026-05-11T23:16:42.000Z - 2 months ago

Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

May 11, 2026, 4:07 PM EDT - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Perspective Therapeutics Earnings release: Q1 2026

Perspective Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Perspective Therapeutics Quarterly report: Q1 2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Apr 24, 2026, 6:30 AM EDT - 2 months ago

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

2026-04-20T10:10:51.000Z - 3 months ago

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Apr 20, 2026, 6:00 AM EDT - 3 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Perspective Therapeutics Proxy statement: Proxy filing

Perspective Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Perspective Therapeutics Proxy statement: Proxy filing

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Apr 2, 2026, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

2026-03-23T10:10:08.000Z - 4 months ago

Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-19T12:28:39.000Z - 4 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

2026-03-18T12:51:16.000Z - 4 months ago

Perspective Therapeutics price target raised to $13 from $11 at B. Riley

Perspective Therapeutics price target raised to $8 from $7 at UBS

2026-03-18T12:07:41.000Z - 4 months ago

Perspective Therapeutics price target raised to $8 from $7 at UBS

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 4:45 PM EDT - 4 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Mar 16, 2026, 4:07 PM EDT - 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics Annual report: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 4 months ago

Perspective Therapeutics Annual report: Q4 2025

Perspective Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 4 months ago

Perspective Therapeutics Earnings release: Q4 2025

Perspective Therapeutics initiated with an Overweight at Piper Sandler

2026-02-19T10:15:14.000Z - 5 months ago

Perspective Therapeutics initiated with an Overweight at Piper Sandler

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Feb 17, 2026, 7:00 AM EST - 5 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

2026-02-02T13:46:01.000Z - 5 months ago

Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Feb 2, 2026, 8:35 AM EST - 5 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

2026-01-30T11:10:55.000Z - 5 months ago

Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 6 months ago

Perspective Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics provides business updates, strategic priorities

2026-01-12T12:40:27.000Z - 6 months ago

Perspective Therapeutics provides business updates, strategic priorities

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

2026-01-09T12:10:58.000Z - 6 months ago

Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Jan 9, 2026, 7:00 AM EST - 6 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:00 AM EST - 7 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 1:00 PM EST - 8 months ago

Perspective Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Perspective Therapeutics assumed with a Buy at Truist

2025-11-24T14:00:51.000Z - 8 months ago

Perspective Therapeutics assumed with a Buy at Truist

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 20, 2025, 7:00 AM EST - 8 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:05 PM EST - 8 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Perspective Therapeutics Quarterly report: Q3 2025

Perspective Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Perspective Therapeutics Earnings release: Q3 2025

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 31, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics Transcript: Study Update

Oct 20, 2025, 8:30 AM EDT - 9 months ago

Perspective Therapeutics Transcript: Study Update

Perspective Therapeutics Press release: Study Update

Oct 20, 2025, 8:30 AM EDT - 9 months ago

Perspective Therapeutics Press release: Study Update

Perspective Therapeutics Slides: Study Update

Oct 20, 2025, 8:30 AM EDT - 9 months ago

Perspective Therapeutics Slides: Study Update

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 9 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 11 months ago

Perspective Therapeutics Quarterly report: Q2 2025

Perspective Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 11 months ago

Perspective Therapeutics Earnings release: Q2 2025

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 1 year ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Quarterly report: Q1 2025

Perspective Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q1 2025

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing

Perspective Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Perspective Therapeutics Proxy statement: Proxy Filing

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Annual report: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Annual report: Q4 2024

Perspective Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 4:00 PM EDT - 1 year ago

Perspective Therapeutics Earnings release: Q4 2024

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Perspective Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 2:00 PM EST - 1 year ago

Perspective Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Transcript: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Status Update

Perspective Therapeutics Press release: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Press release: Status Update

Perspective Therapeutics Slides: Status Update

Jan 24, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Slides: Status Update

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 5, 2024, 10:50 AM EST - 1 year ago

Perspective Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Perspective Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 9:10 AM EST - 1 year ago

Perspective Therapeutics Transcript: Stifel 2024 Healthcare Conference

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Nov 13, 2024, 5:45 PM EST - 1 year ago

Perspective Therapeutics Transcript: UBS Global Healthcare Conference

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Quarterly report: Q3 2024

Perspective Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Perspective Therapeutics Earnings release: Q3 2024

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Alacrity2
Alacrity2 Jul. 15 at 1:52 AM
$CATX I don’t remember seeing this… https://www.linkedin.com/posts/perspective-therapeutics_radiopharmaceuticals-oncology-precisionmedicine-ugcPost-7472649491922477057-7vpq?utm_medium=ios_app&rcm=ACoAACVaBNsBrvfIvbW16ta28vS1MkGGk6XkjWE&utm_source=social_share_video_v2&utm_campaign=share_via
0 · Reply
Raisehellpraisedale
Raisehellpraisedale Jul. 14 at 9:25 PM
$CATX hey yall I’m new here and considering a position after I do some further research. If anyone has some interesting knowledge or information about their products or their personnel I would appreciate links or summaries! So far it seems like an obvious candidate for a BO but I’m only getting started in my process
1 · Reply
noble23
noble23 Jul. 14 at 3:47 PM
$CATX markets up Catx down, Markets down Catx is up? Why? This has been going on for a long time makes no sense.
1 · Reply
Miura1957
Miura1957 Jul. 14 at 3:24 PM
$CATX afternoon rally?
1 · Reply
StockConsultant
StockConsultant Jul. 14 at 1:17 PM
$CATX Perspective Therapeutics stock watch, attempting to move higher off the 3.06 support area at https://stockconsultant.com/?CATX Long Trade Target 1: 3.6 Profit: 16.5% Stop/Trailing Stop: 2.91 Loss: 5.8% P/L ratio: 2.8 : 1 - Good Target 2: 3.83 Profit: 23.9% P/L ratio: 4.1 : 1 - Excellent Extreme rally BULLISH [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom. [Positioning] at support [Timing] Strong bullish 3 day candlestick pattern with Strong 3 day accumulation. [Timing] Strong bullish 1 day moneyflow BEARISH None
0 · Reply
JDinvestments
JDinvestments Jul. 14 at 12:27 PM
$CATX $22 incoming goodluck STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀 👋👋👋🤡🤡🤡 later bitches out !!!
0 · Reply
Newmoves
Newmoves Jul. 14 at 11:32 AM
$CATX what will be the share price when they announce the merger acquisition? $6?
1 · Reply
morty104
morty104 Jul. 14 at 10:35 AM
$CATX up 2, down 6, up 2, down 5, up 2, down 5…math ain’t mathing.
0 · Reply
morty104
morty104 Jul. 14 at 10:33 AM
$CATX YES! They never disappoint; “SEND IN THE ACQUISITION/MERGER/BUYOUT PEOPLE”. Same strategy every time.
0 · Reply
Satann
Satann Jul. 13 at 8:09 PM
$CATX last few weeks look likes share swaps. Are they readying for acquisition?
3 · Reply
rughead64
rughead64 Jul. 13 at 6:09 PM
$CATX strong volume. Nice recovery
0 · Reply
ltcman
ltcman Jul. 13 at 2:37 PM
$CATX for those who have been here for awhile it is hard to believe that we are at $0.29!!!
3 · Reply
Sandmansleeper
Sandmansleeper Jul. 13 at 1:47 PM
$CATX Isoray, Inc. officially changed its name to Perspective Therapeutics and changed its stock ticker from ISR to CATX on February 21, 2023. On that day, the stock opened at $3.66, traded in a range of $3.63 to $3.90, and closed the day at $3.80
1 · Reply
watchaddict
watchaddict Jul. 13 at 1:40 PM
$CATX adding
0 · Reply
morty104
morty104 Jul. 13 at 12:03 PM
$CATX down 5, up 2, down 6, up 2, down 5, up 2….follow the bouncing turd.
0 · Reply
rughead64
rughead64 Jul. 11 at 7:21 PM
$CATX @Miura1957 you are correct. 22.67 million shares shorted
3 · Reply
drdenturedds
drdenturedds Jul. 11 at 4:47 PM
$CATX Number of institutions that are accumulating shares in CATX is changing by the minute. Now we're up to 29 new positions!
0 · Reply
drdenturedds
drdenturedds Jul. 11 at 3:13 PM
$CATX Just saw that they're 23 new positions opened up by institutions last quarter.
0 · Reply
carepolice
carepolice Jul. 10 at 8:28 PM
$CATX replacing Dr. Michael K. Schultz is a big deal and not good for the company
1 · Reply
Miura1957
Miura1957 Jul. 10 at 7:45 PM
$CATX short shares jumped to almost 23M??? Almost 20%….seriously WTF is going on?
2 · Reply
Miura1957
Miura1957 Jul. 10 at 6:59 PM
$CATX started the week with what looked like a move to 4 and will be closing below 3…hope it holds this level and we don’t end up below 2 next week…can’t even sell calls because there is no market.
1 · Reply
CM62
CM62 Jul. 10 at 5:41 PM
$CATX Down again??
0 · Reply